Loading...
Docoh

Vivani Medical (VANI)

Filed: 18 Jul 22, 8:44am

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 14, 2022

 

SECOND SIGHT MEDICAL PRODUCTS, INC.  

(Exact name of registrant as specified in its charter)

 

California 001-36747 02-0692322

(State or other jurisdiction of 

incorporation) 

 

(Commission 

File Number) 

 

(IRS Employer 

Identification No.)  

 

 13170 Telfair Ave 

Sylmar, California

91342
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (818) 833-5000

 

Not Applicable  

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered

Common Stock 

Warrants 

 

EYES 

EYESW 

 

Nasdaq

Nasdaq 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 8.01 Other Events

 

Second Sight Medical Products, Inc. (the “Company”) was notified on July 14, 2022, that the National Institutes of Health (“NIH”) released year four funding in the amount of $1.1 million of the $6.4 million planned five-year grant, 5UH3NS103442. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Early Feasibility Clinical Trial of a Visual Cortical Prosthesis. The Company issued a press release entitled Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study, which is attached to this Current Report as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.

Description 

99.1 Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study dated July 18, 2022. 
104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 SECOND SIGHT MEDICAL PRODUCTS, INC.
  
Date: July 18, 2022By: /s/ Scott Dunbar
  Scott Dunbar
  Acting Chief Executive Officer